ProRata.ai and DPCMO Sign LOI to Enhance Content Consent, Credit, and Compensation in the Age of Generative AI
25.11.2024 15:00:00 CET | Business Wire | Press release
ProRata.ai and The Danish Press Publications’ Collective Management Organisation (DPCMO) have signed a Letter of Intent to explore collaborative opportunities aimed at ensuring fair credit and compensation for the use of Danish media content in the era of generative AI. ProRata.ai, founded by Bill Gross, has developed a proprietary platform that analyzes AI-generated outputs, credits contributing content, and calculates proportional remuneration for content creators. The company's mission is to ensure that generative AI compensates and credits content owners for the use of their material.
DPCMO represents 99% of the Danish news industry and is approved by the Danish Ministry of Culture. The organization’s purpose is to ensure that tech companies benefiting from press publishers’ content contribute to the creative ecosystem transparently and accountably. By partnering with ProRata.ai, DPCMO aims to establish a framework where content creators in Denmark are duly recognized and compensated, fostering a sustainable and equitable digital content ecosystem.
Bill Gross, CEO of ProRata.ai, stated, "Our collaboration with DPCMO underscores our commitment to safeguarding the rights of content creators. By combining our attribution technology with DPCMO's extensive reach in Denmark, we aim to set a new standard for fairness, attribution, and transparency in the generative AI era."
Karen Rønde, CEO of DPCMO, added, "It is a great pleasure to engage with ProRata.ai, which acknowledges that human-made quality content has value. The enhancement of intellectual property rights since the Industrial Revolution has played a crucial role in encouraging innovation, fostering technological progress, and stimulating economic growth. We look forward to exploring business opportunities."
About ProRata.ai
Founded in 2024 by Bill Gross at Idealab Studio, ProRata’s mission is to ensure that generative AI compensates and credits content owners for the use of their material. ProRata builds technology that enables generative AI platforms to attribute contributing content sources and share revenues on a per-use basis, protecting and rewarding creators while helping to prevent unreliable content from compromising AI results. For more information, please visit prorata.ai.
About DPCMO
Founded in 2021, DPCMO is a collective rights management organisation representing Danish media companies and their press publishers neighbouring rights, text and data mining and AI rights. DPCMO represents a diverse circle of members; state-owned public service media, local, regional and national newspapers, magazines, special media, and digitals media outlets. A diverse and vibrant Danish media landscape is essential to democracy.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241125818129/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Egon Zehnder and IMD Join Forces to Boost Board Performance and Leadership Growth12.3.2026 09:00:00 CET | Press release
Egon Zehnder, the world’s premier leadership advisory and executive search firm, and IMD, the leading business school in global executive education, today announced a strategic partnership to facilitate board directors’ personal growth and elevate board performance. The partnership combines IMD's academic rigor and deep connections to global boards with Egon Zehnder's unparalleled expertise in leadership and board effectiveness. Together, they will co-create tailored development experiences that blend research, real-world diagnostics, and practical guidance to support directors navigating today's complex business environment. IMD’s research clearly shows that good governance is a driver of both corporate success and national competitiveness. Egon Zehnder’s global work in supporting the personal development of board directors and chairs has shown that, in times of accelerating change, this has become a decisive factor for success. “This collaboration comes at a pivotal moment,” said Dav
COOLMAX CloakFX™ Fiber Makes Official Global Debut at Performance Days Munich12.3.2026 09:00:00 CET | Press release
The LYCRA Company’s latest innovation minimizes the visible appearance of sweat while delivering moisture management to activewear, ready-to-wear and workwear The LYCRA Company will officially launch COOLMAX CloakFX™ fiber globally at Performance Days Munich, Europe’s leading functional fabric fair, March 18–19. This innovation is designed to help garments appear drier by minimizing visible sweat marks while delivering moisture management and cooling comfort. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317950119/en/ COOLMAX CloakFX™ fiber, the latest innovation from The LYCRA Company, helps garments appear drier by minimizing visible sweat marks and delivering moisture-wicking, cooling performance. Photo credit: The LYCRA Company COOLMAX CloakFX™ fiber is for brands, mills, and garment makers creating performance-driven activewear, workwear, and everyday apparel. The technology diffuses light at the fiber level using o
EcoOnline Launches Mega Trends Report as 2025 Momentum Reflects the Shift from Compliance to Connected Risk12.3.2026 09:00:00 CET | Press release
Eighteen months of EcoOnline primary research highlights seven shifts reshaping safety and sustainability, mirrored in the company’s 2025 customer adoption, product innovation, and growth. EcoOnline, a leading global provider of safety and sustainability software, today announced its inaugural EcoOnline Mega Trends Report, based on 18 months of primary research with business leaders and frontline workers. Seven mega trends reshaping the risk landscape The findings show a market-wide sense of urgency and shift towards connected risk data and vendor consolidation, with organisations increasingly treating compliance as the baseline while prioritising improved operations visibility, faster decision-making, and a need to future-proof their businesses with real-time insights and operational readiness. The report outlines seven macro trends, from the chemical safety maturity gap and the rise of lone work and contractor reliance to the central role of training and frontline engagement, and the
Redslim expands into Asia-Pacific to support global brands with data and AI infrastructure12.3.2026 07:00:00 CET | Press release
Redslim, a specialist in end-to-end data management solutions and an Astorg portfolio company, today announced its expansion into the Asia-Pacific region and the appointment of Kyriakos Zannikos as Regional Director, APAC. The move marks an important milestone in Redslim’s global growth strategy and brings the company closer to clients operating in one of the world’s fastest-growing and most data-driven consumer markets. As global consumer brands accelerate digital transformation and AI adoption, many organizations still struggle with fragmented data ecosystems spanning multiple agencies, markets and datasets. These challenges are particularly pronounced in Asia-Pacific, where diverse market structures and rapid growth create complex data environments. Redslim helps organizations transform fragmented market information into valuable data assets, empowering clients to make confident decisions and unlock the full value of their data. By building strong data foundations, Redslim supports
Meiji Seika Pharma Initiates Phase I Clinical Trial in Australia Evaluating ME3241, an Anti-PD-1 Agonist Antibody Discovered Through Collaborative Research With FBRI12.3.2026 07:00:00 CET | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) announced today that it has initiated a Phase I clinical trial of ME3241 (development code), an anti-PD-1 agonist monoclonal antibody discovered through collaborative research with the Foundation for Biomedical Research and Innovation at Kobe (Headquarters: Kobe, Japan; President: Shuh Narumiya; hereinafter “FBRI”). The Phase I clinical trial is designed as a randomized, placebo-controlled, double-blind study, with the objective of evaluating the safety and tolerability of ME3241 following single and multiple dosing, as well as its pharmacokinetics and pharmacodynamics (ClinicalTrials.gov: NCT07422207). ME3241 was discovered through a collaborative research program led by Program Director Tasuku Honjo, a professor emeritus at Kyoto University. PD-1 is a molecule expressed on activated T cells and other lymphocytes that suppresses immune responses. Through this re
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom